natgillin/translations-raw huggingface dataset:
An object of the present invention resides in the use of a combination of Cladribine and IFN-beta for the manufacture of a medicament for treating patients suffering from multiple sclerosis and who are refractory to at least one conventional therapy for multiple sclerosis, wherein Cladribine is to be orally administered following the sequential steps below: 
HR P20120382 T1 PATENTNI ZAHTJEVI Uporaba kombinacije Kladribina i IFN-beta za proizvodnju lijeka za liječenje pacijenata koji imaju multiplu sklerozu i koji su otporni na barem jedan uobičajen način liječenja multiple skleroze, naznačena time da se Kladribin daje oralno u skladu sa niže navedenim uzastopnim koracima:
The crude product was triturated with petroleum ether and filtered to afford 51.63g of pure product as a yellow solid. 
Sirovi produkt triturira se petroleterom, te filtrira kako bi se dobilo 51,63 g čistog produkta u obliku žute krutine.
The information system according to any of claims 1 to 9, wherein the reflector is provided to a lower portion of the optical element. 
Informacijski sustav u skladu sa bilo kojim od patentnih zahtjeva 1 do 8, gdje je reflektor osiguran na nižem dijelu optičkog elementa.
a CDKL5 polypeptide sequence, wherein the CDKL5 polypeptide sequence comprises SEQ ID NO: 2 or SEQ ID NO: 16; and a TATk polypeptide sequence, wherein the TATk polypeptide sequence has about 90% to about 100% sequence identity to SEQ ID NO: 4, wherein the TATk polypeptide is operatively coupled to the CDKL5 polypeptide. 
Fuzijski protein za uporabu u liječenju nedostatka CDKL5, Rettovog sindroma ili atipičnog Rettovog sindroma uzrokovanog mutacijom ili nedostatkom CDKL5, te fuzijski protein sadrži: CDKL5 polipeptidnu sekvencu, pri čemu CDKL5 polipeptidna sekvenca sadrži SEQ ID NO: 2 ili SEQ ID NO: 16; i TATk polipeptidnu sekvencu, pri čemu TATk polipeptidna sekvenca ima oko 90% do oko 100% istovjetnosti sekvence prema SEQ ID NO: 4, pri čemu je TATk polipeptid operativno spojen s CDKL5 polipeptidom.
A composition according to claim 1 which contains a co-herbicide selected from the group consisiting of aryloxy- and heteroaryloxyphenoxy propionic acids, cyclohexanediones, sulfonyl ureas, triazolopyrimidines, nitriles, thiocarbamates, dinitroanilines, benzoic acids, phenoxy acids and pyridine carboxylic acids. 
Pripravak prema zahtjevu 1 naznačen time da sadrži ko-herbicide odabrane iz skupine koja obuhvaća ariloksi- i heteroariloksifenoksi propionske kiseline, cikloheksandione, sulfonil uree, triazolopirimidine, nitrile, tiokarbamate, dinitroaniline, benzojeve kiseline, fenoksi kiseline i piridin karboksilne kiseline.
Decreased dopamine activity in the mesocortical tract (as seen in the schizophrenic patient) results in an inability for the prefrontal areas of the brain to activate. 
Smanjeno dopaminsko djelovanje u mezokortikalnom traktu (kao što je vidljivo kod šizofrenih pacijenata) rezultira nemogućnošću aktiviranja prefrontalnih područja mozga.
A crumb for a crumb coated food product manufactured by a method comprising the steps of: 
Postupak proizvodnje prehrambenih proizvoda sa zrnatom koricom koji obuhvaća korake:
a second layer, which comprises the sustained release polymer and optionally binder and plasticizer, which layer is coated on layer (b) or optional layer (d) and optionally a separating layer, which is coated on layer (b), i.e. 
Cc) drugi sloj, koji sadrži polimer za produljeno otpuštanje, a izborno i vezivo i plastifikator, gdje se taj sloj oblaže na sloj (b) ili izborni sloj (d), te d) izborni separacijski sloj, kojeg se oblaže na sloj (b), tj.
wherein the respective first coupling elements are asymmetrical and are respectively provided in the form of a left-hand design and a right-hand design, 
Zaštitna kaciga (2) prema zahtjevu 1 ili 2, naznačena time da su prvi spojni elementi (7) zasebno formirani u obliku lijevostrane i desnostrane izvedbe.
The method according to claim 1, wherein the rear fin parts are configured with triangular cross section, corresponding to the tubular shape of the front penetrator part. 
Raspored prema zahtjevu 1, naznačen time da su stražnji dijelovi stabilizatora (9, 9") konfigurirani s trokutastim presjekom, koji odgovara cjevastom obliku prednjeg dijela penetratora (10).
A method of preparing a cell having adenovirus E1A and E1B-I9K and E1B-55K coding sequences integrated into its genome, the method comprising the steps of introducing into a precursor cell: a single nucleic acid molecule comprising the E1A and E1B-19K and E1 B-55K coding sequences, wherein said E1A and at least one of the E1B coding sequences are separated by at least 8 kb; or two or more nucleic acid molecules comprising the E1A and E1B-19K and E1B-55K coding sequences wherein said E1A and at least one of the E1B coding sequences are separated by at least 8 kb when said two or more nucleic acid molecules would form a single molecule by end-to-end joining. 
Postupak pripreme stanice koja ima adenovirus EIA i E1B-I9K i E1B-55K kodirajuće sekvence integrirane u njezin genom, naznačen time da postupak sadrži korake uvođenja u prekursorsku stanicu: jednostruke molekule nukleinske kiseline koja sadrži ELA 1 E1B-19K i El B-55K kodirajuće sekvence, pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb; ili dvije ili više molekula nukleinske kiseline sadrži ELA 1 E1B-19K 1 E1B-55K kodirajuće sekvence pri čemu navedena E1A 1 barem jedna od E1B kodirajućih sekvenci su odvojene sa barem 8 kb kada bi navedene dvije ili više molekula nukleinske kiseline mogle tvoriti jednostruku molekulu spajanjem kraja sa krajem.
The pharmaceutical composition for use according to embodiment 30 or 31 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (1) m je pozitivan cijeli broj 1 R12, R2 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (1) n je pozitivan cijeli broj 1 R2, R32 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
A process for preparing nebivolol hydrochloride Form T1 comprising the steps of: (a) dissolving nebivolol hydrochloride in an alcohol to form a clear solution; 
Materijal je profiltriran nakon čega je slijedio dodatak metanola (800,0 ml) i zagrijavanje na 60-65 "C da bi se dobilo bistru otopinu.
When turned on, the transmitter automatically and continuously sends signals, to the receiver, the signals being representative of the state of the respective switches on the transmitter. 
Kad je odašiljač uključen, automatski i kontinuirano šalje signale prijemniku, s time da signali odražavaju stanje pojedinih sklopki odašiljača.
The method according to claim 1, wherein the red blood cells (1) encapsulate said tumor antigen and (2) are in the form of an immune complex with an immunoglobulin which recognizes an epitope at the surface of the red blood cells, so as to promote phagocytosis of said red blood cells by dendritic cells. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da crvene krvne stanice (1) sadrže antigen i (2) u obliku su imunološkog kompleksa s imunoglobulinom koji prepoznaje epitop na površini crvenih krvnih stanica, tako da potiču fagocitozu navedenih crvenih krvnih stanica putem dendritskih stanica.
The present invention relates to a cigarette type smoking article which produces an aerosol that resembles tobacco smoke, and which contains no more than a minimal amount of incomplete combustion or pyrolysis products, as defined in the preamble of claims 1 and 2. 
(54) Naziv izuma: CIGARETNI SUBSTITUT (57) Sažetak: = Pronalazak se odnosi na proizvod za pušenje koji proizvodi aerosol koji je sličan duhanskom dimu, ali sadrži samo minimalnu količinu proizvoda nekompletnog sagorijevanja ili pirolize.
The pharmaceutical composition according to claim 1, comprising said Form I of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and said excipient in a ratio of about 1:8 by weight. 
Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačen time da sadrži navedenu 1-[3-(4-bromo-2-metil-2H- pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-ureu i navedenu pomoćnu tvar u omjeru od oko 1:8 po masi.
EPMATHMARKEREP denoting the average non-reference b frame sizes per GOP; 
[image], koji označuje prosjek veličina nereferentnog b kadra po GOP-u;
a zinc finger nuclease; or a Transcription Activator-Like Effector Nuclease (TALEN). 
(a) cink nukleazu; (b) Transkripcijsku efektornu nukleazu poput aktivatora (TALEN).
The combination for use as claimed in any one of claims 1 to 3, wherein about 0.05 mg/ml to about 7.0 mg/ml of the ((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate are applied with about 2% of a carbonic anhydrase inhibitor to an eye of the subject from 1 to 4 times daily. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, pri čemu se otprilike 0.05 mg/mL do otprilike 7.0 mg/mL ((2R,3$,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-il)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrata primjenjuje s otprilike 2% inhibitora karboanhidraze u oko subjekta I do 4 puta na dan.
Likewise, trans-(+)-A9-THC in the presence of a non-polar organic solvent and trans-(-)-A9-THC in the presence of a non-polar organic solvent can be admixed. 
(c) formiranje prvog sastava koji sadrži trans-(-)-A'-tetrahidrokanabinol iz koraka (b), trans-(+)-A'- tetrahidrokanabinol, te nepolarno organsko otapalo. .
Magnetic optically variable pigments which can be used for the embodiment of the invention have been disclosed in US 4,838,648; in EP 686,675 B1; as well as in WO 02/73250 A2 and in WO 03/00801 A2; the latter two describe the best suited pigments to solve the stated technical problem. 
Magnetski optički varijabilni pigmenti koji se mogu koristiti u utjelovljenjima sukladno predmetnom izumu opisani su u US 4,838,648; EP 686,675 B1; kao 1u WO 02/73250 A2 i WO 03/00301 A2; u zadnja dva dokumenta opisuju se najprikladnije vrste pigmenta za rješavanje navedenih tehničkih problema.
In one embodiment, the invention provide an in vitro diagnostic method for the diagnosis of endometrial cancer or an increased likelihood of endometrial comprising detecting the level of (1) from 1 to 17 biomarker(s) chosen from ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, and TJP3 in a sample from a patient wherein an increased level of said from 1 to 17 biomarkers compared to a control value indicates a diagnosis of endometrial cancer or increased likelihood of endometrial cancer and/or (2) detecting the level of from 1 to 3 biomarkers chosen from EFEMP2, SOCS2, and DCN, wherein a decreased level of EFEMP2, SOCS2, and/or DCN compared to a control value indicates a diagnosis of endometrial cancer or increased likelihood of endometrial cancer. 
Postupak dijagnosticiranja in vitro u skladu s bilo kojim od patentnih zahtjeva 1 do 15 i 17 do 20, naznačen time što se sastoji u osiguravanju uzoraka maternične tekućine uzetog iz pacijentice uz pomoć pipele ili injekcijske šprice, gdje pacijentica posjeduje čimbenik rizika ili pokazuje simptom raka endometrija; miješanju navedenog uzorka sa sredstvom koje može konzervirati, spriječiti ili smanjiti razgradnju RNA u navedenom uzorku maternične tekućine; određivanju u navedenom uzorku razine eksprimiranja mRNA koja odgovara navedenom biomarkeru P4HB i, izborno, jednom biomarkeru koji se bira između ACAAI1, APIM2, CGN, DDR1, EPS8L2, FASTKDI, GMIP, IKBKE, P2RX4, PHKG2, PPFIBP2, PPPIRI6A, RASSF7, RNF183, SIRT6, TIP3, EFEMP2, SOCS2 i DCN, i jednog ili više endogenih gena uz pomoć kvantitativnog PCR;
Aclidinium for use according to any preceding claim, wherein the aclidinium is in the form of a dry powder formulation suitable for inhalation. 
Aklidinij za primjenu prema bilo kojem od prethodnih zahtjeva, naznačen time, što se aklidinij nalazi u obliku formulacije suhog praha prikladnog za inhalaciju.
the 4-1BB signalling region is encoded by SEQ ID NO: 17 and the CD3 zeta signalling domain is encoded by SEQ ID NO:18; 
signalno područje 4-1BB je kodirano sekvencom SEQ ID NO: 17 i signalno područje CD3 zeta je kodirano sekvencom SEQ ID NO:18;
The capsule of claim 11 wherein said shell comprises gelatin, cellulose, starch or HPMC. 
Kapsula u skladu sa zahtjevom 11, naznačena time, da navedena školjka sadrži želatinu, celulozu, škrob ili HPMC.
Pertuzumab for use according to claim 7 wherein the antimetabolite chemotherapeutic agent is gemcitabine. 
Pertuzumab za uporabu prema zahtjevu 7, naznačen time, da antimetaboličko kemoterapeutsko sredstvo je gemcitabin.
The base station apparatus according to one of claims 1 to 9, wherein said allocating unit is adapted to map, in the second allocation, Localized Virtual Resource Blocks, LVRBs, to PRBs, and to allocate the LVRBs to the mobile station apparatus in units of the RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
A pharmaceutical composition according to claim 3 wherein the one or more additional active ingredients is selected from an anti-inflammatory agent, an analgesic agent, a pain reliever, a potentiator, a decongestant, an antitussive, a diuretic and a sedating or non-sedating antihistamine. 
Farmaceutska smjesa prema zahtjevu 3 gdje se jedna ili više dodatnih djelatnih tvari izabire između protu-upalnog sredstva, analgetika, sredstva protiv bolova, potencijatora, dekongestiva, sredstva protiv kašlja, diuretika te antihistaminika s ili bez sedativnog svojstva.
Because the color was less than 2000 APHA, these batches were considered free of metal ion impurities. In a process for obtaining a mixture of trifluoroacetyl glatiramer acetate, wherein the mixture has a desired average molecular weight and wherein during the process a batch of a mixture of polypeptides, each of which consists of alanine, Y-benzyl glutamate, tyrosine and trifluoroacetyl lysine is deprotected with a solution of hydrobromic acid in acetic acid, the improvement comprising use of a solution of hydrobromic acid in acetic acid, which solution comprises less than 0.1% of free bromine. 
Glatiramer acetat, naznačen time, da nema više od 0,1% bromiranog tirozina i da ima manje od 1000 ppm nečistoća metalnim ionima. Glatiramer acetat prema patentnom zahtjevu 11, naznačen time, da ima prosječnu molekulsku masu od 4700 daltona do 11000 daltona. Postupak za proizvodnju glatiramer acetata, naznačen time, da sadrži stupanj skidanja zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, pri čemu poboljšanje sadrži: prethodnu obradu otopine bromovodične kiseline u octenoj kiselini hvatačem broma prije primjene otopine za skidanje zaštite sa zaštićenog glatiramer acetata,
Optionally, the method includes incorporating in each of the sensor arrangements of the one or more containers a waste status sensor arrangement for determining a volume of waste in a corresponding waste container, and a spatial position determining sensor for determining a spatial location of the corresponding waste container. 
- uključivanje u svaki od senzorskih sklopova (30, 40) iz jednog ili više spremnika (20) sklopa senzora statusa otpada za određivanje volumena otpada u odgovarajućem spremniku otpada (20), i senzora za određivanje prostorne lokacije za određivanje prostorne lokacije odgovarajućeg spremnika otpada (20), naznačen time da postupak dodatno obuhvaća
The system (100) as claimed in claim 1, wherein the first request is a request to update General Packet Radio Service location of the mobile subscriber from a Serving General Packet Radio Service Supporting Node associated with the visited network operator. 
Sustav (100) temeljem zahtjeva 1, naznačen timešto je prvi zahtjev zahtjev za ažuriranje GPRS lokacije mobilnog pretplatnika kod GPRS čvorišta za podršku povezanog sa posjećenim registrom lokacija.
The method according to claim 14, wherein the cell membrane protein is Fc receptor Y-chain. 
Metoda prema zahtjevu 13, naznačena time da je ta bjelančevina stanične membrane y- lanac receptora za konstantni Fc-fragment protutijela.
a host cell transformed with an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1 and an expression vector comprising a polynucleotide comprising the base sequence encoding the light chain variable region of the antibody; a host cell transformed with an expression vector comprising a polynucleotide comprising the base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1; and 
(b) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje teškog lanca protutijela protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1(1) i ekspresijski vektor koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje lakog lanca protutijela; (c) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje teškog lanca protutijela protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1(1);1
A process for the preparation of a compound of formula (5) comprising coupling a compound of formula (3) 
Postupak za dobivanje spoja formule (5): koji obuhvaća kupliranje spoja formule (3):
The preparation of Compound (C) or a pharmaceutically acceptable salt thereof comprises: (g) reacting Compound (A): 
(a) reakciji Spoja (X), ili njegove farmaceutski prihvatljive soli, sa Spojem (Y)
(in the formula, Ts represents p-toluenesulfonyl, Et represents ethyl, and R1 represents lower alkyl). 
(u formuli Ts predstavlja p-toluensulfonil, Et predstavlja etil, a R' predstavlja nerazgranati ili razgranati C,galk1l).
Packaging unit according to one or more of the foregoing claims, wherein the label comprises a two- sided print. 
Jedinica za pakiranje prema jednom ili više od prethodnih zahtjeva, naznačena time da naljepnica sadrži dvostrani tisak.
X is selected from the group consisting of halogen, -CN, -CO2R15, -C(=O)NR15R16,-NR15R16, -OR15, -SO2R7, and -P(=O)R8R9; and R15 and R16 independently are selected from the group consisting of H, acyl, alkenyl, alkoxyl, OH, NH2, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heterocyclyl, and heterocyclylalkyl may be substituted or unsubstituted; and optionally R15 and R16 together with the N to which they are bonded may form a heterocycle which may be substituted; 
Ris je izabran iz grupe koju čine (Â«C=O)ORis, -OR:s, alkil 1 aril, pri čemu svaki alkil 1 aril mogu biti supstituirani; 1 Ris je izabran iz grupe koju čine H, acil, alkenil, alkoksil, OH, NH,, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil, gde svaki acil, alkenil, alkoksil, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil može biti supstituiran; i njegovi enantiomeri, diastereomeri, tautomeri, farmaceutski prihvatljive soli, hidrati, solvati i kompleksi. Spoj prema patentnom zahtjevu 1 predstavljen strukturom: šo
frequency deinterleaving the L1 signaling data and the L1 header in the signal frame; time deinterleaving the frequency-deinterleaved L1 signaling data by serially writing the frequency-deinterleaved L1 signaling data into a memory in a row direction and reading the written L1 signaling data from the memory in a diagonal direction according to the L1 TI mode information, wherein a number of rows of the memory is equal to the time interleaving depth, wherein a number of columns of the memory is equal to a quotient resulting from dividing a number of cells corresponding to the L1 signaling data by the time interleaving depth, and wherein the time interleaving depth is equal or larger than a minimum number of OFDM symbols required for carrying an L1 block including the L1 signaling data; 
vremenska među-pohrana mapa vrijednosti skupa koje odgovaraju sloju 1 odašiljanih podataka, temeljenih na memoriji sukladno L1 TI načinu informiranja koji pokazuje dubinu vremenske među-pohrane, gdje je broj redaka memorije jednak dubini vremenske među-pohrane, a broj stupaca memorije jednak je kvocijentu podjele broja vrijednosti skupa koje su potrebne za prijenos simbola potrebnih za prijenos L1 odašiljanih podataka, dok je dubinu vremenske među-pohrane jednaku ili veću od minimalnog broja OFDM simbola potrebnih za prijenos L1 odašiljanih podataka; umetanje zaglavlja sloja 1 u vremenski među-pohranjene vrijednosti skupa koje odgovaraju sloju 1 odašiljanih podataka, gdje zaglavlje sloja 1 uključuje L1 TI način informiranja;
15-75 wt.% of a highly unsaturated oil selected from the group consisting of sunflower oil, soybean oil, rapeseed oil, cottonseed oil, safflower oil, marine oil, corn oil, olive oil, linseed oil and combinations thereof; and 
- 15-75%, težinski, visoko nezasićenog ulja, koje se bira iz skupine koju čine suncokretovo ulje, sojino ulje, ulje iz sjemena uljane repice, ulje iz sjemena pamuka, šafranikino ulje, riblje ulje, kukuruzno ulje, maslinovo ulje, ulje iz sjemena lana i njihove kombinacije; i
Advantageously the protein variant is capable of stimulating an immune response against Tat proteins from HIV-1 subtypes A, B, C, D, and E (E subtype HIV strains are observed mainly in South East Asia but are often considered as recombinant forms of A subtype strains). 
Protein za uporabu u prevenciji ili liječenju AIDS kod pacijenta prema zahtjevima 1 do 3, naznačen time da protein može stimulirati imuni odgovor protiv Tat proteina iz dva, tri, četiri, pet ili više podtipova HIV-1 koji su odabrani od A, B,C,D,E,F,G, H,J,iK.
The reaction may conveniently be performed in a suitable inert solvent or diluent. 
Reakcija se može prikladno provesti u prikladnom inertnom otapalu ili razrjeđivaču.
at least one receiver, arranged to receive signals transmitted by the emergency service transmitter. 
- < najmanje jednim prijemnikom (R), podešenim za prijem signala koje šalje odašiljač hitne službe (T),
The ink or coating composition is furthermore preferably selected from the group of liquid inks, comprising screen-printing inks, gravure inks and flexographic inks. 
Tinta ili smjesa za premazivanje se osim toga poželjno odabire iz skupine koju čine tekuće tinte, među koje spadaju i tinte za tiskanje zaslonom, tinte za graviranje 1 fleksografske tinte.
The EBC colour value of the beer samples was determined as well as the reduction in MBT content versus the control sample, using the MBT analysis described in Example 3. 
Određena je EBC vrijednost boje uzoraka piva, kao i smanjenje sadržaja MBT u odnosu na kontrolni uzorak, pomoću analize MBT opisane u primjeru 3.
A proteinaceous complex, comprising (i) a light chain and a heavy chain of an antibody; and (ii) a fusion polypeptide comprising, from N-terminus to C-terminus, an immunoregulator fused to an antibody Fc region, optionally via a linker; 
Bjelančevinasti kompleks, koji sadrži (1) teški lanac i laki lanac antitijela specifičnih za tumorski antigen; i (2) fuzijski protein koji se sastoji od, od N-kraja do C-kraja, jedan ili više imunoregulatora spojenih na područje antitijela Fc, opcionalno pomoću jednog ili više veznika, pri čemu područje antitijela Fc (2) kompleksa s teškim lancem (1) tvori heterodimer.
A composite stainless steel and wood barrel according to claim 1 wherein said barrel body comprises an upper part and said upper part of said barrel body is slightly curved. 
Kombinirana bačva od nehrđajućeg čelika i drva prema jednom od patentnih zahtjeva 1 do 5, naznačena time da su gornji 1 donji dijelovi bačve blago zakrivljeni što omogućava bolje istakanje.